4D Molecular Therapeutics, Inc. - Common Stock (FDMT)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Mar 28, 2026Investment Snapshot
- P/B of 0.92 — trading below book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -40.2%
- Revenue growing at 230,195% annually
4D Molecular Therapeutics, Inc. - Common Stock (FDMT) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $464 million . Key value metrics: P/B ratio 0.92, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
4D Molecular Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, FDMT shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -40.2% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.15.
StockPik's composite Value Score for FDMT is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
FDMT shows revenue growing at 230,195% year-over-year, with earnings growing at 13%.